Dengue Fever News and Research

RSS

Dengue fever is a mosquito-borne tropical disease caused by the dengue virus. Symptoms typically begin three to fourteen days after infection. These may include a high fever, headache, vomiting, muscle and joint pains, and a characteristic skin rash.

Inviragen receives two grants to develop dengue and chikungunya vaccines

Inviragen, a biotechnology company developing vaccines to protect against infectious diseases worldwide, announced today that it has received two grants totaling $488,958 through the United States government's Qualifying Therapeutic Discovery Project Program.

3 Nov 2010

Halting mosquito surveillance can increase management costs of epidemics 300 times

Cutting surveillance for mosquito-borne diseases would likely translate into an exponential increase in both the number of human cases and the health costs when a disease outbreak occurs, according to an analysis by Emory University.

27 Oct 2010

Northern Territory reports worst mosquito plague ever

Authorities in Australia’s Northern Territory report the worst mosquito plague since records began in 1979. An organization helping homeless people in Darwin is distributing insect repellent and coils to combat the mosquito onslaught.

25 Oct 2010

Inviragen commences Phase 1 clinical trial of DENVax dengue vaccine in Colombia

Inviragen, a company developing vaccines to protect against infectious diseases worldwide, and the Program for the Study and Control of Tropical Diseases (PECET), jointly announced the initiation of a Phase 1 clinical trial of DENVax™ in Colombia. DENVax is an investigational vaccine designed to provide protection against all four dengue virus serotypes. The trial will measure the safety of DENVax as well as the immune responses induced by the vaccine in healthy adults in Rionegro, Colombia.

25 Oct 2010

LSUHSC receives NIH grant for research on cancer and infectious diseases

LSU Health Sciences Center New Orleans has been awarded $12 million over five years by the National Institutes of Health to conduct research on diseases like prostate and stomach cancers, lymphoma and leukemia, dengue fever, tuberculosis, and herpes infections, as well as to support the development of academic research scientists.

21 Oct 2010

NanoViricides' President delivers speech at ASNM Second Annual Conference

NanoViricides, Inc. announced today that the Company President was invited to and presented a talk at the Second Annual Conference of the American Society for NanoMedicine (ASNM).

18 Oct 2010

WHO Western Pacific meeting addresses immunization, TB control, women's health

The WHO Regional Committee for the Western Pacific meeting continued with leaders discussing regional immunization goals, public health emergencies, TB control, and the health effects of urbanization, multiple news outlets report.

15 Oct 2010

NanoViricides files financial year end annual report with SEC

NanoViricides, Inc. reports that it has filed its financial year end annual report (Form 10K) with the Securities and Exchange Commission (SEC) yesterday in a timely manner.

14 Oct 2010

Officials discuss leadership, donor commitments, eliminating leprosy at start of WHO Western Pacific Region Committee Session

The WHO "must demonstrate strong leadership backed by impeccable technical competency, [Malaysian] Prime Minister Datuk Seri Najib Tun Razak said" at the opening ceremony of the 61st Session of the WHO Regional Committee for the Western Pacific Monday, Bernama reports.

13 Oct 2010

WHO Western Pacific meeting to address maternal health, rise in dengue

Maternal health and dengue fever are among the issues that will be discussed at the 61st session of the WHO Regional Committee for the Western Pacific, Bernama reports.

12 Oct 2010

Dengue fever spreads in Asia, WHO warns 2.5B people at risk

The WHO "has warned that 2.5 billion people are at risk" of dengue fever, "which has 'grown dramatically in recent decades,'" Agence France-Presse reports. WHO officials cite higher temperatures, growing populations and international travel for the "rapid rise in urban mosquito populations" and in dengue. Seventy percent of the at-risk population is in Asia, the WHO said.

8 Oct 2010

NIAID announces three new contracts to fund research on dengue, anthrax vaccines

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, today announced three new contracts to fund research on vaccines to protect against emerging infectious diseases and biological threats that could be used in a terror attack. Each project focuses on simple and efficient vaccine delivery approaches that could be deployed quickly. The total funding for the three contracts could reach $68 million, depending on the successful completion of defined project milestones.

8 Oct 2010

Inviragen, PharmaJet awarded NIAID contract to develop needle-free, easy to administer dengue vaccine

Inviragen and PharmaJet announced the award of a five year, $15.5 million dollar contract from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to advance the development of a needle-free, easy to administer dengue vaccine. The award will fund preclinical studies, regulatory filings, manufacturing and clinical testing of Inviragen's tetravalent dengue vaccine, DENVax delivered with PharmaJet's convenient needle-free injection device.

8 Oct 2010

Researchers examine new genes to control mosquito-borne diseases

An Iowa State University researcher searched for new genes that are turned on during infection in a type of mosquito that is not only a pest, but transmits disease-causing pathogens.

4 Oct 2010

Tamir's compounds perform better than Ganciclovir for Cytomegalovirus disease: Study

Tamir Biotechnology, Inc. announced today that scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID) reported test results confirming two of our lead compounds outperformed market leader Roche's drug Ganciclovir in cell culture and plaque reduction assay (the gold standard) for Cytomegalovirus (CMV) disease. Additionally, antiviral activity was also apparent against other human herpesviruses, namely, HSV-1 (cold sores), HSV-2 (genital herpes), and Varicella-Zoster Virus (VZV) (chicken-pox and shingles).

29 Sep 2010

ASTMH recommends FDA to include neglected infections of poverty in orphan classification

Today, U.S. scientists committed to finding answers to reducing and eliminating what are known as neglected tropical diseases (NTDs) that plague the world's poorest people in developing countries, urged the FDA to include in its orphan classification the neglected infections of poverty that also affect Americans, and expressed support for stronger relationships with the FDA to ultimately halt these ancient scourges.

24 Sep 2010

Dengue fever vaccine in the pipeline

Australians researchers are moving towards producing the first ever vaccine for dengue fever, the potentially life-threatening infection spread by mosquitoes in the tropics. At present late stage clinical trials are underway for a vaccine that would protect against all four known strains of the disease. Participants are now being recruited in Perth, Adelaide and Brisbane.

20 Sep 2010

395 new vaccines being developed for infectious diseases: PhRMA

Critical challenges remain in the centuries-old battles against infectious diseases, particularly as bacteria and viruses mutate and as the threat of bioterrorism grows. Responding to this need, America's biopharmaceutical research companies this year have 395 new medicines and vaccines in the pipeline to fight infectious diseases. All 395 are in later stages of development, meaning in clinical trials or under Food and Drug Administration (FDA) review.

10 Sep 2010

Global warming may eliminate plague

While many climate experts and environmentalists explore the negative effects of global warming, a new study reveals a positive outcome of the warming of the planet: the potential elimination of the plague. Global warming affects temperatures and precipitation regimes that play a pivotal role in the lives of rodents and fleas; rodents and fleas are responsible for maintenance and spread of plague to human populations. Plague can be fatal if the symptoms are not recognized and treated within 24 hours.

8 Sep 2010